|Day's Range||84.72 - 85.14|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.95|
|Dividend & Yield||2.72 (3.27%)|
|1y Target Est||N/A|
Roche, Celgene and Novartis could change the multiple sclerosis landscape, a sector now dominated by Biogen.
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.